AVI Kurz vor dem Ziel / AVI BioPharma Announces FDA Clearance of IND

Kurs zieht an...
AVI BioPharma, Inc.
(NasdaqGM: AVII)

NEW Real-time: 0.8399 + 0.3499 (71.41%)

laber

Vor dem Ziel? 5-10 Jahre und hunderte Mio $ von dem Ziel.

Allerweltsmeldung.

New Drug Applications verteilen die fast zu 99% an alle. Auch den 98% von den 99%, die dann später sterben. So wird es vermutlich auch hier sein.

Haben ein bisschen wenig Cash. Aber da es sich um RNA Antisense WS Pipeline handelt, stehen die Chancen mE sehr gut, dass die rel. schnell Partner bekommen. Und jetzt ist eigentlich die Zeit reif. Denn Biotechs mit Antisense Pipeline haben bezügl Partnerschaften iM sehr wenig Probleme. Und dann kommt uU die nötige Kohle rein.

Antwort auf Beitrag Nr.: 36.264.461 von -Salem- am 24.12.08 19:36:36tach zusammen...schaut euch mal telik an...
heute schon angelaufen..denke mal die news
kommen nach

Antwort auf Beitrag Nr.: 36.264.453 von -Salem- am 24.12.08 19:26:46Allerweltsmeldung.

New Drug Applications verteilen die fast zu 99% an alle. Auch den 98% von den 99%, die dann später sterben. So wird es vermutlich auch hier sein.


Dafür das es eine Allerweltsmeldung gewesen sei soll ...lief es echt Prima!
Leider konnte ich nicht verkaufen ...das war wohl weniger toll... wird wohl so enden, so gewonnen so zerronnen.....

ich nehme es sportlich....

Läuft doch!!! Aushalten ist alles!!!!

Potential bis 2 $ in den kommenden
Tagen.
Wichtig:
Nur als Zock ansehen.
Viele andere "flu virus shares" sind schon
heißgelaufen.

Mon, Apr 27, 2009
07:08 AM

NanoViricides, Inc. Says Flu-Cide Drug Designed to Destroy All Influenza A Viruses Including Swine and Bird Flu

NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced that it is developing FluCide(™), its flagship anti-influenza drug candidate, to work against all influenza types and subtypes. FluCide has been shown to be effective against both common influenza subtype H1N1, as well as two different variants of bird flu subtype H5N1.

The Company has previously announced excellent results in both animal studies and cell culture studies against widely different influenza subtypes and strains. If these results are confirmed in further animal and human studies, then FluCide would likely be considered the best ever drug effective against all influenzas. The Company is communicating its capabilities to various agencies involved in the current epidemic response.

The current swine flu outbreak is significant in that the H1N1 virus causing it is novel (http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/news/apr2109swine.html). The US Department of Homeland Security has declared a Swine Flu Emergency yesterday. The WHO has said that the outbreak is an emergency of international concern (http://www.upi.com/Health_News/2009/04/26/DHS-declares-swine-flu-emergency/UPI-53711240725694/). The pig is known to be a transitional species for influenza viruses. That means re-assortment (i.e. mixing) of genes from bird flu, human flu, and swine flu viruses can take place in pigs. This can lead to more lethal, drug resistant novel strains to emerge from different existing ones.

"Nanoviricides(™) have clear advantages over antibodies and vaccines as antiviral strategies," said Dr. Diwan, President of NanoViricides. Antibodies are relatively specific to a particular virus strain or subtype. It is well known that HIV and influenza viruses among many others, quickly escape antibodies. Vaccines depend upon the development of antibodies by the host, and thus, cannot protect efficiently against those viruses which are continually changing their character, such as the influenza virus. Influenza vaccines in particular have to be developed with the strain that is expected to infect in the next year’s cycle. It is well known that this is not a failure-proof strategy for epidemic-causing strains that are novel.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.




NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com